Bavani Rajah1, Pablo J Sánchez2, Cristina Garcia-Maurino1, Amy Leber3, Octavio Ramilo4, Asuncion Mejias5. 1. Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, OH. 2. Center for Perinatal Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Division of Neonatology, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, OH; Division of Pediatric Infectious Diseases, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, OH. 3. Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, OH. 4. Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Division of Pediatric Infectious Diseases, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, OH. 5. Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Division of Pediatric Infectious Diseases, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, OH. Electronic address: Asuncion.Mejias@nationwidechildrens.org.
Abstract
OBJECTIVES: To determine the differences in number of respiratory syncytial virus (RSV) hospitalizations and outcomes in infants 290/7-346/7 weeks' gestational age (wGA) the season before (season 1 [S1]; 2013-2014) and after (season 2 [S2]; 2014-2015) implementation of the 2014 American Academy of Pediatrics revised guidance for palivizumab prophylaxis. STUDY DESIGN: Children <12 months of age hospitalized with RSV infection were identified by the International Classification of Diseases, Ninth Revision codes and virology reports. Clinical, outcome data, palivizumab eligibility, and hospital charges were compared among infants 29-34 wGA in S1 vs S2. RESULTS: Of 1063 RSV hospitalizations in infants <12 months old, 7.1% (34/482) in S1 and 9.8% (57/581) in S2 occurred in 290/7-346/7 wGA infants. On the other hand, 29-34 wGA infants who were <6 months old constituted 3.5% (17/482) of RSV hospitalizations in S1 vs 7.1% (41/581) in S2 (P = .01). Among 290/7-346/7 wGA healthy infants who were <3 months old, oxygen administration (40.0% vs 78.9%; P = .05), pediatric intensive care unit admission (30.0% vs 68.4%; P = .04), mechanical ventilation (10.0% vs 52.6%; P = .04), duration of hospitalization (1.8 vs 8.8 days; P = .04), and hospital charges ($19 686 vs $30 662; P = .03) significantly increased in S2 vs S1. No differences in morbidity were observed in premature infants who were 3 to <6 and 6 to <12 months between seasons. Palivizumab eligibility decreased from 32.3% in S1 to 1.8% in S2 (P < .001). One infant died in each season. CONCLUSIONS: In the year following implementation of the 2014 palivizumab prophylaxis guidance, there was an increase in RSV hospitalizations and associated morbidity among 29-34 wGA infants of younger chronological age.
OBJECTIVES: To determine the differences in number of respiratory syncytial virus (RSV) hospitalizations and outcomes in infants 290/7-346/7 weeks' gestational age (wGA) the season before (season 1 [S1]; 2013-2014) and after (season 2 [S2]; 2014-2015) implementation of the 2014 American Academy of Pediatrics revised guidance for palivizumab prophylaxis. STUDY DESIGN:Children <12 months of age hospitalized with RSV infection were identified by the International Classification of Diseases, Ninth Revision codes and virology reports. Clinical, outcome data, palivizumab eligibility, and hospital charges were compared among infants 29-34 wGA in S1 vs S2. RESULTS: Of 1063 RSV hospitalizations in infants <12 months old, 7.1% (34/482) in S1 and 9.8% (57/581) in S2 occurred in 290/7-346/7 wGA infants. On the other hand, 29-34 wGA infants who were <6 months old constituted 3.5% (17/482) of RSV hospitalizations in S1 vs 7.1% (41/581) in S2 (P = .01). Among 290/7-346/7 wGA healthy infants who were <3 months old, oxygen administration (40.0% vs 78.9%; P = .05), pediatric intensive care unit admission (30.0% vs 68.4%; P = .04), mechanical ventilation (10.0% vs 52.6%; P = .04), duration of hospitalization (1.8 vs 8.8 days; P = .04), and hospital charges ($19 686 vs $30 662; P = .03) significantly increased in S2 vs S1. No differences in morbidity were observed in premature infants who were 3 to <6 and 6 to <12 months between seasons. Palivizumab eligibility decreased from 32.3% in S1 to 1.8% in S2 (P < .001). One infant died in each season. CONCLUSIONS: In the year following implementation of the 2014 palivizumab prophylaxis guidance, there was an increase in RSV hospitalizations and associated morbidity among 29-34 wGA infants of younger chronological age.
Authors: M Cetinkaya; T K Oral; S Karatekin; B Cebeci; A Babayigit; Y Yesil Journal: Eur J Clin Microbiol Infect Dis Date: 2017-04-08 Impact factor: 3.267
Authors: Mitchell Goldstein; Leonard R Krilov; Jaime Fergie; Kimmie K McLaurin; Sally W Wade; David Diakun; Gregory M Lenhart; Adam Bloomfield; Amanda M Kong Journal: Am J Perinatol Date: 2018-06-19 Impact factor: 1.862
Authors: Amanda M Kong; Leonard R Krilov; Jaime Fergie; Mitchell Goldstein; David Diakun; Sally W Wade; Melissa Pavilack; Kimmie K McLaurin Journal: Am J Perinatol Date: 2017-09-07 Impact factor: 1.862